Prodrugs of CL316243: a selective beta3-adrenergic receptor agonist for treating obesity and diabetes.

Abstract

CL316243 is a highly selective and potent beta3-adrenergic receptor agonist, and has been shown in rodent models to be an effective agent for treating obesity and Type II diabetes. To improve the oral absorption and pharmacokinetic profiles of CL316243, a number of prodrugs have been synthesized and evaluated. Several ester-type prodrugs show significant improvements in oral bioavailability in both rodent and primate models.

• Authors: F W Sum, A Gilbert, A M Venkatesan, K Lim, V Wong, M O'Dell, G Francisco, Z Chen, G Grosu, J Baker, J Ellingboe, M Malamas, I Gunawan, J Primeau, E Largis, K Steiner
• Journal: Bioorganic & medicinal chemistry letters (Bioorg Med Chem Lett) Vol. 9 Issue 14 Pg. 1921-6 (Jul 19 1999) ISSN: 0960-894X [Print] England
• PMID: 10450954 (Publication Type: Journal Article)

Chemical References

• Adrenergic beta-Agonists
• Dioxoles
• Esters
• Fatty Acids
• Hypoglycemic Agents
• Prodrugs
• disodium (R,R)-5-(2-((2-(3-chlorophenyl)-2-hydroxyethyl)-amino)propyl)-1,3-benzodioxole-2,3-dicarboxylate

Topics

• Adrenergic beta-Agonists (chemistry, metabolism, pharmacology)
• Animals
• Biological Availability
• Diabetes Mellitus, Experimental (drug therapy)
• Diabetes Mellitus, Type 2 (drug therapy)
• Dioxoles (pharmacology)
• Esters (chemistry, metabolism)
• Fatty Acids (blood)
• Half-Life
• Haplorhini
• Humans
• Hydrolysis
• Hypoglycemic Agents (pharmacology)
• Mice
• Obesity (drug therapy)
• Prodrugs (chemistry, metabolism, pharmacology)
• Rats